A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, ...

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, ...

The Cocoon® (from Lonza) is a functionally closed, sterile, efficient manufacturing platform, which combined with our ...

Evidence of active autoimmune myocardial inflammation can be detected through assays of peripheral blood that identify and quantify circulating heart-homing c-Met + memory T cells. Phenotyping these T ...

Imagine cells navigating through a complex maze, guided by chemical signals and the physical landscape of their environment.

bNational Institute of Health and Care Research (NIHR) Blood and Transplant Research Unit (BTRU) in Precision Cellular Therapeutics, University of Birmingham, Birmingham, UK cNIHR Biomedical Research ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments ...

Their study is based on a large-scale meta-analysis of single-cell RNA sequencing and T-cell receptor (TCR) sequencing from cancer patients treated with immunotherapy. This allowed them to examine ...

This review explores recent advances in the characteristics and manufacturing of CAR T-cell products. Traditional potency assays have been designed based on well-established CAR T-cell functionalities ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...